Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,135,170
  • Shares Outstanding, K 182,743
  • Annual Sales, $ 1,860 M
  • Annual Income, $ 859,100 K
  • 60-Month Beta 0.58
  • Price/Sales 7.57
  • Price/Cash Flow 61.27
  • Price/Book 3.44
Trade BMRN with:

Options Overview

Details
  • Implied Volatility 34.07%
  • Historical Volatility 17.64%
  • IV Percentile 29%
  • IV Rank 15.59%
  • IV High 74.43% on 01/08/21
  • IV Low 26.62% on 05/28/21
  • Put/Call Vol Ratio 0.55
  • Today's Volume 253
  • Volume Avg (30-Day) 1,298
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 46,727
  • Open Int (30-Day) 50,427

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate 0.05
  • Number of Estimates 7
  • High Estimate 0.14
  • Low Estimate -0.04
  • Prior Year 0.07
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.42 +2.50%
on 07/23/21
86.33 -9.27%
on 06/28/21
-6.46 (-7.62%)
since 06/25/21
3-Month
74.43 +5.24%
on 05/11/21
86.33 -9.27%
on 06/28/21
-1.44 (-1.81%)
since 04/27/21
52-Week
71.35 +9.78%
on 09/11/20
124.52 -37.09%
on 08/05/20
-45.67 (-36.83%)
since 07/27/20

Most Recent Stories

More News
Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY

Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.

GSK : 39.52 (+1.28%)
NVS : 91.32 (+0.40%)
BIIB : 333.96 (+0.61%)
BMY : 67.49 (-0.30%)
JNJ : 172.66 (+0.46%)
PFE : 42.10 (+0.69%)
BMRN : 78.33 (+1.27%)
TLRY : 12.73 (-7.08%)
Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

Arvinas (ARVN) collaborates with Pfizer for its investigational breast cancer candidate, ARV-471. Pfizer is also set to acquire an equity stake in Arvinas. The stock rises 9% post the announcement.

PFE : 42.10 (+0.69%)
BMRN : 78.33 (+1.27%)
ARVN : 94.05 (-0.87%)
NMTR : 1.1000 (-0.90%)
Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers

Novartis (NVS) reports mixed results for the second quarter, as key brands maintain momentum and businesses show signs of recovery.

REGN : 581.01 (+0.56%)
NVS : 91.32 (+0.40%)
BMRN : 78.33 (+1.27%)
BGNE : 269.25 (-1.96%)
Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug

Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.

BMRN : 78.33 (+1.27%)
EXAS : 111.95 (-1.30%)
ALBO : 28.31 (-3.97%)
TVTX : 13.76 (+2.00%)
BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstrating Continued, Durable Clinical Benefit

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today new data for valoctocogene roxaparvovec, an investigational gene therapy treatment for adults with severe hemophilia A, from...

BMRN : 78.33 (+1.27%)
Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX

The biotech sector was in focus last week on updates form Regeneron (REGN) and Bristol Myers (BMY).

REGN : 581.01 (+0.56%)
BMY : 67.49 (-0.30%)
BMRN : 78.33 (+1.27%)
VRTX : 202.85 (+1.97%)
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced new data for valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia...

BMRN : 78.33 (+1.27%)
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment

Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.

BMRN : 78.33 (+1.27%)
EXAS : 111.95 (-1.30%)
ACAD : 21.15 (-0.66%)
SYBX : 3.21 (+3.55%)
BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

RHHBY : 47.3000 (+1.15%)
PFE : 42.10 (+0.69%)
BMRN : 78.33 (+1.27%)
SGMO : 9.60 (-0.72%)
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the European Medicines Agency (EMA) validated the Company's Marketing Authorization Application (MAA) for its investigational...

BMRN : 78.33 (+1.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment...

See More

Key Turning Points

3rd Resistance Point 81.05
2nd Resistance Point 79.78
1st Resistance Point 79.05
Last Price 78.33
1st Support Level 77.05
2nd Support Level 75.78
3rd Support Level 75.05

See More

52-Week High 124.52
Fibonacci 61.8% 104.21
Fibonacci 50% 97.93
Fibonacci 38.2% 91.66
Last Price 78.33
52-Week Low 71.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar